<DOC>
	<DOCNO>NCT00192348</DOCNO>
	<brief_summary>Trial compare safety tolerability one two dos influenza virus vaccine .</brief_summary>
	<brief_title>A Prospective , Randomized , Double-Blind , Placebo-Controlled Trial Assess Safety Tolerability Influenza Virus Vaccine , ( CAIV-T ) Healthy Infants</brief_title>
	<detailed_description>The objective study compare safety tolerability one two dos influenza virus vaccine , trivalent , type A B , live cold-adapted liquid ( CAIV-T ) placebo administer intranasally healthy infant age 6 &lt; 24 week .</detailed_description>
	<criteria>child least 6 week age le 24 week age time enrollment , &gt; 37 week gestational age birth weight &gt; 2500 g , good health determine medical history , physical examination clinical judgment ; whose parent/legal guardian provide write informed consent nature study explain ; , along parent legal guardian , available three month duration trial ( enrollment study completion ) ; whose parent ( ) /legal guardian ( ) , could reach study staff postvaccination contact [ telephone , clinic home visit ] . whose parent legal guardian perceive unavailable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down â€™ syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; cytotoxic agent ; receive blood product , include immunoglobulin , period birth conclusion study ; immunosuppressed immunocompromised individual living household ; document history hypersensitivity egg egg protein component study vaccine placebo ; administer live virus vaccine within one month prior enrollment ; expect receive another live vaccine within 1 month vaccination study . intent administer investigational vaccine agent one month prior enrollment conclusion study ; receive dose influenza treatment ( commercial investigational ) two week prior enrollment . The prophylactic use influenza antiviral permit ; , anytime prior study enrollment , receive influenza vaccine ( commercial investigational ) ; respiratory illness wheeze within two week prior dose study vaccine ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrollment use anticipate study ; medical condition opinion investigator might interfere interpretation study result . Note : Pregnancy person regular contact subject consider contraindication enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>24 Weeks</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>